Severe Influenza Trial of ARbidol

NCT ID: NCT03787459

Last Updated: 2025-06-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-01-18
• Study Completion Date: 2024-10-17

Brief Summary

This is a multicenter, randomised, double-blind, controlled study to assess the efficacy and safety of arbidol plus oseltamivir, compared with oseltamivir alone in approximately 200 hospitalized adults and adolescent patients with confirmed severe influenza. Patients should be randomised as soon as possible after screening (no later than 12 hours), providing they are within 7 days of symptom onset. Patients will be assigned in a 1:1 ratio to receive an arbidol plus oseltamivir, or oseltamivir plus placebo. Rescreening of patients who fail to meet the inclusion and exclusion criteria will be permitted only once, providing the time from symptom onset to randomization is still within 7 days.

Arbidol/placebo will be administrated as 200mg TID from Days 1-7. Oseltamivir will be administered as 75mg twice daily from Days 1-7 (dose to be adjusted for renal impairment). Oseltamivir could be continued till influenza PCR negative. Both drugs, along with the corresponding placebo for arbidol, will be started at the time of randomization.

Conditions

Influenza

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

oseltamivir plus placebo

Group Type: ACTIVE_COMPARATOR

Placebos

Intervention Type: DRUG

Oseltamivir plus placebos will be administrated from Days 1-7.

oseltamivir plus arbidol

Group Type: EXPERIMENTAL

Arbidol

Intervention Type: DRUG

Oseltamivir plus Arbidol will be administrated from Days 1-7.

Interventions

Arbidol

Oseltamivir plus Arbidol will be administrated from Days 1-7.

Intervention Type: DRUG

Placebos

Oseltamivir plus placebos will be administrated from Days 1-7.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Hospitalized males or females with a positive antigen or PCR test for influenza virus infection

2. Age ≥16 years at the time of signing Informed Consent Form

3. Arterial oxygen saturation (SaO2)/ pulse oxygen saturation (SPO2) ≤94% in room air condition

4. ≤ 7 days since symptom onset. The onset of symptoms is defined as either: Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature- ≥38℃); Time when the patient experiences at least one general or respiratory symptom.

5. Willingness to use contraception for 7 days after the end of treatment

Exclusion Criteria

1. Physicians make a decision that trial involvement is not in patients' best interest, or any condition that does not allow the protocol to be followed safely.

2. Patient refusal to accept invasive organ support treatment if needed

3. More than 3 consecutive doses of NAIs within 2 days before enrolment (including oseltamivir, zanamivir, peramivir)

4. Women who are pregnant (including a positive pregnancy test at enrolment), breastfeeding, or within 2 weeks post-partum.

The following female subjects do not need to undergo a pregnancy test at enrolment: a. Postmenopausal (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test) women. b. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation.

5. Any condition requiring renal replacement therapy

6. Severe liver disease (Child-Pugh score ≥ C)

7. A history of hypersensitivity to arbidol or oseltamivir (Tamiflu®)

8. Currently or have been involved in another anti-influenza treatment trial in the last 28 days

9. Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions

• Minimum Eligible Age: 16 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Oxford

OTHER

Sponsor Role: collaborator

Peking University

OTHER

Sponsor Role: collaborator

National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention

OTHER_GOV

Sponsor Role: collaborator

Capital Medical University

OTHER

Sponsor Role: lead

Responsible Party

Bin Cao

China-Japan Friendship Hospital

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

CAP-China Arbidol

Identifier Type: -

Identifier Source: org_study_id